AHA Hypertension 2026: Efficacy and Safety of the Selective Aldosterone Synthase Inhibitor Lorundrostat in Moderate-to-Severe Apnea and Hypertension: Explore-OSA Randomized Crossover Trial
AHA Hypertension 2026: Blood Pressure Responder Analysis in the Global Launch-HTN Trial of Lorundrostat in Uncontrolled and Resistant Hypertension
AHA Hypertension 2026: Lorundrostat Mitigates Cardiorenal Injury Independent of Blood Pressure Reduction in an L-NAME/Angiotensin II Rat Model
AHA Hypertension 2026: Real-world Utilization and Treatment Patterns of Spironolactone in Patients with Hypertension
AHA Hypertension 2026: Adherence to Mineralocorticoid Receptor Antagonists for Uncontrolled and Treatment-Resistant Hypertension: A Targeted Literature Review and Meta-Analysis
ENDO 2026: Lorundrostat Modulates Heart Failure Risk Biomarkers in Participants With Uncontrolled Hypertension
ESH 2026 Presentation: Lorundrostat for Hypertension in CKD: Results From the LAUNCH-HTN Trial
ASN 2025: Lorundrostat, a Novel Aldosterone Synthase Inhibitor (ASI), in Participants with Uncontrolled Hypertension, CKD, and Albuminuria: Results from Explore-CKD
